Journal: Scientific Reports

Article Title: Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer

doi: 10.1038/s41598-018-27355-8

Figure Lengend Snippet: CD55 expression in human lung cancer tissue.

Article Snippet: A 1:200 dilution of the anti-CD55 polyclonal antibody (AP14798A; Abgent) was used for all analyses.

Techniques: Expressing, Staining

Journal: Scientific Reports

Article Title: Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer

doi: 10.1038/s41598-018-27355-8

Figure Lengend Snippet: CD55 expression in human lung cancer tissue. ( a ) Immunohistochemical analysis of CD55 in lung tissue. i, normal lung; ii, lung adenosquamous carcinoma; iii, lymph node metastatic carcinoma from lung adenocarcinoma; iv, lung mucoepidermoid carcinoma; v, lung squamous cell; vi, lung adenocarcinoma; vii, lung large cell carcinoma; viii, lung bronchioloalveolar carcinoma. Scale bars = 100 μm. Insets are magnified images demonstrating CD55 expression on the cell membrane and in the cytoplasm. ( b ) Immunohistochemical analysis of CD55 expression in normal organs. i, spleen; ii, lung; iii, skeletal muscle; iv, kidney; v, rectum; vi, colon; vii, stomach; viii, liver. Scale bars = 100 μm.

Article Snippet: A 1:200 dilution of the anti-CD55 polyclonal antibody (AP14798A; Abgent) was used for all analyses.

Techniques: Expressing, Immunohistochemical staining

Journal: Scientific Reports

Article Title: Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer

doi: 10.1038/s41598-018-27355-8

Figure Lengend Snippet: Development of chimeric CD55-specific monoclonal antibodies. ( a ) Phage ELISA results for individual clones tested against recombinant human CD55. A total of 384 clones were tested for binding to recombinant human CD55 (Supplementary Fig. ). The data for 36 clones are shown. ( b ) Reactivity of three anti-CD55 IgGs to recombinant human CD55 analyzed by antigen-binding ELISA. ( c ) SDS-PAGE analysis of the Ab1 anti-CD55 IgG antibody. ( d ) Representative flow cytometry analysis of H460 and H69 cells stained with the Ab1 anti-CD55 antibody.

Article Snippet: A 1:200 dilution of the anti-CD55 polyclonal antibody (AP14798A; Abgent) was used for all analyses.

Techniques: Enzyme-linked Immunosorbent Assay, Clone Assay, Recombinant, Binding Assay, SDS Page, Flow Cytometry, Staining

Journal: Scientific Reports

Article Title: Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer

doi: 10.1038/s41598-018-27355-8

Figure Lengend Snippet: Characterization of 177 Lu-DTPA-anti-CD55 in vitro . ( a ) Representative results of three independent Lindmo assays to examine binding of 177 Lu-anti-CD55 to H460 cells. ( b ) Representative results of three independent saturation binding assays of 177 Lu-anti-CD55 in H460 cells. ( c ) Blocking assays in H460, H358, H69, and WI-38 cells (n = 3; **P < 0.01; Student’s t test). The results are presented as the mean ± standard error of the mean (SEM; error bars).

Article Snippet: A 1:200 dilution of the anti-CD55 polyclonal antibody (AP14798A; Abgent) was used for all analyses.

Techniques: In Vitro, Binding Assay, Blocking Assay

Journal: Scientific Reports

Article Title: Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer

doi: 10.1038/s41598-018-27355-8

Figure Lengend Snippet: Biodistribution analysis of 177 Lu-anti-CD55 in vivo . ( a ) The biodistribution of 177 Lu-anti-CD55 in tissue from pleural metastatic mice (n = 3–6 per condition). The results are presented as the mean ± SD (error bars). ( b ) The biodistribution of 177 Lu-anti-CD55 in normal lung and lung tumor tissue from pleural metastatic mice (n = 3–6 per condition; **P < 0.01; Student’s t test). The results are presented as the mean ± SD (error bars). ( c ) Excretion and residual radioactivity after injection of 177 Lu-anti-CD55 into mice. ( d ) Micro-SPECT/CT images of pleural metastatic or control mice treated with 177 Lu-anti-CD55. The amount of radioactivity is calculated in MBq/cc.

Article Snippet: A 1:200 dilution of the anti-CD55 polyclonal antibody (AP14798A; Abgent) was used for all analyses.

Techniques: In Vivo, Radioactivity, Injection, Micro-SPECT

Journal: Scientific Reports

Article Title: Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer

doi: 10.1038/s41598-018-27355-8

Figure Lengend Snippet: Biodistribution of the 177 Lu-anti-CD55 antibody in a pleural metastatic mouse model.

Article Snippet: A 1:200 dilution of the anti-CD55 polyclonal antibody (AP14798A; Abgent) was used for all analyses.

Techniques:

Journal: Scientific Reports

Article Title: Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer

doi: 10.1038/s41598-018-27355-8

Figure Lengend Snippet: Effects of the 177 Lu-anti-CD55 antibody on invasion and migration in lung cancer cells. ( a ) The invasive front of squamous cell carcinoma in the lung (arrows). Scale bars = 50 μm. ( b ) Invasion and migration of H460 cells treated with IgG, anti-CD55, or 177 Lu-anti-CD55. ( c ) Invasion and migration were quantified by counting cells in ten randomly selected regions (***P < 0.001; Student’s t test). The results are presented as the means ± SEM (error bars).

Article Snippet: A 1:200 dilution of the anti-CD55 polyclonal antibody (AP14798A; Abgent) was used for all analyses.

Techniques: Migration

Journal: Scientific Reports

Article Title: Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer

doi: 10.1038/s41598-018-27355-8

Figure Lengend Snippet: Therapeutic efficacy of the 177 Lu-anti-CD55 antibody in vitro and in vivo . ( a ) Assays of H460 lung cancer cell viability after treatment with IgG, 177 Lu-IgG, anti-CD55, or 177 Lu-anti-CD55. α-CD55 (μg/ml) indicates the concentration of all the antibodies, IgG, 177 Lu-IgG, α-CD55, and 177 Lu-α-CD55. 177 Lu-α-CD55 (MBq) indicates the corresponding amounts of radioactivity of 177 Lu-α-CD55 for the indicated concentration (n = 3; **P < 0.01; Student’s t test). The results are presented as the mean ± SEM (error bars). ( b ) Assays of H358 cell viability after treatment with IgG, 177 Lu-IgG, anti-CD55, or 177 Lu-anti-CD55 (n = 3; *P < 0.05; Student’s t test). The results are presented as the mean ± SEM (error bars). ( c ) Effects of 177 Lu-anti-CD55 on the survival of H460 bearing-early pleural metastatic mice (n = 10 for each group; ***P < 0.001; Log-rank (Mantel-Cox) test). ( d ) Effects of 177 Lu-anti-CD55 on the survival of pleural metastatic mice (n = 10 for each group; **P < 0.01; Log-rank (Mantel-Cox) test).

Article Snippet: A 1:200 dilution of the anti-CD55 polyclonal antibody (AP14798A; Abgent) was used for all analyses.

Techniques: In Vitro, In Vivo, Concentration Assay, Radioactivity

Journal: Scientific Reports

Article Title: Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer

doi: 10.1038/s41598-018-27355-8

Figure Lengend Snippet: Combinatorial effects of 177 Lu-anti-CD55 and cisplatin in vitro and in vivo . ( a ) Cell viability assays of H460 lung cancer cells treated with 0.1 MBq of 177 Lu-anti-CD55 in the presence or absence of 3 μM cisplatin (n = 3; *P < 0.05; Student’s t test). The results are presented as the mean ± SEM (error bars). ( b ) Cell viability assays of H358 lung cancer cells treated with 0.1 MBq of 177 Lu-anti-CD55 in the presence or absence of 3 μM cisplatin (n = 3; *P < 0.05; Student’s t test). The results are presented as the mean ± SEM (error bars). ( c ) Effects of 177 Lu-anti-CD55 in the presence or absence of cisplatin on the survival of early pleural metastatic mice (n = 10 for each group; ***P < 0.001; Log-rank (Mantel-Cox) test). ( d ) Analysis of the survival of pleural metastatic mice after treatment with 177 Lu-anti-CD55 in the presence or absence of cisplatin (n = 10 for each group).

Article Snippet: A 1:200 dilution of the anti-CD55 polyclonal antibody (AP14798A; Abgent) was used for all analyses.

Techniques: In Vitro, In Vivo